<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1732">
  <stage>Registered</stage>
  <submitdate>30/10/2007</submitdate>
  <approvaldate>30/10/2007</approvaldate>
  <nctid>NCT00552045</nctid>
  <trial_identification>
    <studytitle>Epilepsy Phenome/Genome Project</studytitle>
    <scientifictitle>Epilepsy Phenome/Genome Project: A Phenotype/Genotype Analysis of Epilepsy</scientifictitle>
    <utrn />
    <trialacronym>EPGP</trialacronym>
    <secondaryid>CRC</secondaryid>
    <secondaryid>1R01NS053998-01A1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epilepsy</healthcondition>
    <healthcondition>Localization-related Epilepsy</healthcondition>
    <healthcondition>Infantile Spasms</healthcondition>
    <healthcondition>Lennox-Gastaut Syndrome</healthcondition>
    <healthcondition>Polymicrogyria</healthcondition>
    <healthcondition>Periventricular Heterotopias</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>subject - individuals with epilepsy

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>EPGP will recruit persons with specific forms of epilepsy. DNA will be isolated from participants' blood and genetic variants associated with common forms of epilepsy will be identified.</outcome>
      <timepoint>over 4.5 years</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Current age from 4 weeks to 60 years.

          -  Clear diagnosis of epilepsy, i.e., a lifetime history of two or more unprovoked
             seizures.

          -  Age at first unprovoked seizure younger than 40 years.

          -  High quality clinical and laboratory data (i.e., neuroimaging, EEG) must be available
             throughout the patient's history

          -  All patients with localization-related epilepsy (LRE) or idiopathic generalized
             epilepsy (IGE) must have a first-degree relative (parent, child, or sibling) with
             non-symptomatic (idiopathic or cryptogenic) epilepsy who is willing and available to
             participate.

          -  All patients with infantile spasms (IS), Lennox-Gastaut syndrome (LGS), or
             malformations of cortical development (MCD) must have both biological parents
             available and willing to participate.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Clinical and laboratory data do not allow a clear determination of whether the patient
             has epilepsy, or whether the diagnosis is LRE, IGE, IS, LGS, or MCD.

          -  Exclusively febrile seizures or other acute symptomatic seizures.

          -  Identified antecedent cause of epilepsy (i.e., a structural or metabolic insult to the
             CNS prior to the first unprovoked seizure, such as stroke, brain tumor, severe head
             trauma, etc., or a progressive neurodegenerative disorder).

          -  Recognized genetic syndrome (e.g., tuberous sclerosis, neurofibromatosis, Rett's or
             Angelman's syndromes) or chromosomal abnormality. (e.g., aneuploidies, unbalanced
             translocations, or chromosomal deletions and duplications detectable by conventional
             medical karyotyping).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>4150</actualsamplesize>
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>University of Melbourne - Melbourne</hospital>
    <postcode>3081 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of California, San Francisco</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institute of Neurological Disorders and Stroke (NINDS)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to collect detailed information about the characteristics and
      genetics of a large number of individuals with epilepsy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00552045</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniel Lowenstein, MD</name>
      <address>University of California, San Francisco, Department of Neurology</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>